Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.

Journal of hematology & oncology - 14 Nov 2025

Cortes Jorge, Curti Antonio, Fenaux Pierre, Jonas Brian A, Krauter Jürgen, Montesinos Pau, Récher Christian, Taussig David C, Wang Eunice S, Watts Justin, Wei Andrew, Yee Karen Wl, Tian Hua, Sheppard Aaron, Marzac Christophe, de Botton Stephane

Abstract excerpt

BACKGROUND: Olutasidenib is an oral, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML) based on a registrational, phase 2, open-label, multicenter trial. METHODS: Results from the pre-planned interim analysis were previously published (data cut-off [DCO]: June 2021). In this final-follow up analysis, we report an additional 2...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Antineoplastic Agents
Follow-Up Studies
Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Leukemia, Myeloid, Acute

Source

Open in PubMed Open full text

Identifiers

PMID: 41239466
DOI: 10.1186/s13045-025-01751-w
PMCID: PMC12619413

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.PMID 41239466Read ↗

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).Semantic proximity Read ↗

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLSemantic proximity Read ↗

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.Semantic proximity Read ↗

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.Semantic proximity Read ↗

Olutasidenib: First Approval.Semantic proximity Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.Semantic proximity Read ↗

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.Semantic proximity Read ↗

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.